StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.91−0.24 (-20.87%)

Close on Nov 18, 2026Market cap $19.92MP/E –Yield –

Aardvark Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aardvark Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$73.96M. For fiscal 2025 it was -$62.73M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$62.73M–
FY2024Dec 31, 2024-$22.79M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.08M–
Q1 FY2026Mar 31, 2026-$22.46M–
Q4 FY2025Dec 31, 2025-$18.70M–
Q3 FY2025Sep 30, 2025-$17.70M–
Q2 FY2025Jun 30, 2025-$15.85M–
Q1 FY2025Mar 31, 2025-$10.47M–
Q4 FY2024Dec 31, 2024-$9.45M–
Q3 FY2024Sep 30, 2024-$5.09M–
Q2 FY2024Jun 30, 2024-$6.07M–
Q1 FY2024Mar 31, 2024-$2.17M–

More Aardvark Therapeutics figures

See a number that looks wrong?